Last reviewed · How we verify

NCT03057041

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

Completed NA Last updated 13 June 2018
What this trial tests

NA trial testing Fentanyl in Pain Uterus in 107 participants. Completed in 30 May 2018.

Timeline
23 March 2017
Primary endpoint
30 May 2018
30 May 2018

Quick facts

Lead sponsorUniversity of Hawaii
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment107
Start date23 March 2017
Primary completion30 May 2018
Estimated completion30 May 2018
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Hawaii

Who can join

14 and older, female only, with Pain Uterus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intranasal fentanyl has been found to be safe and effective in the reduction of pain among pediatric and adult populations. The investigators hypothesize that patients who receive 100 mcg of intranasal fentanyl for pain control before first-trimester uterine aspiration will report lower pain scores than those who receive placebo. The investigators will test this hypothesis using a randomized, double-blind, placebo-controlled trial comparing pain reported during uterine aspiration between patients who receive either intranasal fentanyl or intranasal saline prior to the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fentanyl

Trials testing the same drug.

Other University of Hawaii trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03057041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing